SQLite Web: event

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-18T13:13:35.877203+00:00","dedupe_key":"signal_enriched:discovery_unusual_volume_delta:597af7faf90f7461","evidence_event_ids":["evt_f685cbec068a"],"signal_type":"discovery_unusual_volume_delta","source":"discovery_ingestor","value":{"aggregator_url":"https://www.nasdaq.com/articles/johnson-johnson-buy-after-its-q1-2026-earnings-report","as_of":"2026-04-18T13:13:35.877203+00:00","canonical_url":"https://www.fool.com/investing/2026/04/18/is-johnson-johnson-buy-after-q1-2026-earnings/","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/johnson-johnson-buy-after-its-q1-2026-earnings-report","article_chars":3276,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_0ec58e3dd6379e91","canonical_host":"fool.com","canonical_is_aggregator":false,"canonical_url":"https://www.fool.com/investing/2026/04/18/is-johnson-johnson-buy-after-q1-2026-earnings/","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-18T13:14:07.284227+00:00","extraction_method":"trafilatura","fetched_description":"Key PointsJohnson & Johnson exceeded expectations in its Q1 2026 earnings report.","fetched_title":"Is Johnson & Johnson a Buy After Its Q1 2026 Earnings Report? | Nasdaq","final_url":"https://www.nasdaq.com/articles/johnson-johnson-buy-after-its-q1-2026-earnings-report","html_truncated":false,"paywall_likely":false,"publisher_domain":"fool.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/johnson-johnson-buy-after-its-q1-2026-earnings-report","source_event_id":"evt_f685cbec068a","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"0129204c1cb86575","kind":"unusual_volume","published_at":"2026-04-18T12:50:00+00:00","publisher_domain":"fool.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.74,"dates_mentioned":["Q1 2026","Q1 2025","last year","April 18, 2026"],"entities":[{"asset_class":"equity","name":"Johnson & Johnson","relevance":"high","symbol":"JNJ","type":"company"},{"asset_class":"other","name":"Stelara","relevance":"high","symbol":"","type":"drug"},{"asset_class":"other","name":"Darzalex","relevance":"medium","symbol":"","type":"drug"},{"asset_class":"other","name":"Tremfya","relevance":"medium","symbol":"","type":"drug"}],"event_type":"earnings","information_gaps":["Unusual volume details are not provided in the text: baseline volume, volume ratio vs average, and direction are missing.","No explicit statement confirms whether the volume change (if any) is confirmed by news versus unexplained; the article discusses earnings reaction and product sales rather than trading-volume metrics.","A specific catalyst hypothesis for unusual volume is not stated; the closest discussed catalyst is the muted earnings reaction tied to Stelara sales decline and patent expiration."],"key_facts":["The article states Johnson & Johnson exceeded expectations in its Q1 2026 earnings report.","The article states Johnson & Johnson conservatively boosted its guidance for the year.","The article states the stock price was slightly lower following the Q1 2026 results release and has been down over the last several days.","The article states Darzalex generated roughly $4 billion in sales in Q1 2026.","The article states Tremfya generated $1.6 billion in sales in Q1 2026.","The article states Stelara\u2019s patent expired last year and sales fell from $1.6 billion in Q1 2025 to $656 million in Q1 2026 due to increased generic competition.","The article states the company has increased its dividend payout for 64 consecutive years.","The article states the article\u2019s author/analyst framing suggests there may be limited near-term news to move the stock in either direction."],"numeric_claims":[{"label":"Darzalex sales (Q1 2026)","value":"~$4 billion"},{"label":"Tremfya sales (Q1 2026)","value":"$1.6 billion"},{"label":"Stelara sales (Q1 2025)","value":"$1.6 billion"},{"label":"Stelara sales (Q1 2026)","value":"$656 million"},{"label":"Johnson & Johnson shares up over last year","value":"more than 52%"}],"primary_claim":"Johnson & Johnson beat Q1 2026 earnings estimates and modestly increased guidance, but investors reacted mutedly and the stock has fallen recently, largely tied to Stelara sales dropping after patent expiration.","relevance_score":0.62,"sentiment":"mixed","source_quality":"high","summary":"The article says Johnson & Johnson (JNJ) beat Q1 2026 earnings expectations and conservatively boosted full-year guidance, but the stock response was muted and the shares have been down over the last several days. It attributes the concern to weakening Stelara sales due to patent expiration and increased generic competition.","topics":["Q1 2026 earnings","guidance","stock price reaction","Stelara patent expiration","generic competition","drug sales performance","dividend stability","drug pipeline"]},"source":"Nasdaq Markets","source_domain":"fool.com","summary":"Key PointsJohnson & Johnson exceeded expectations in its Q1 2026 earnings report.","tickers":[],"title":"Is Johnson & Johnson a Buy After Its Q1 2026 Earnings Report?","url":"https://www.fool.com/investing/2026/04/18/is-johnson-johnson-buy-after-q1-2026-earnings/"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

event_store.db — events

Update row 189982 in events